|1.||Puri, Raj K: 54 articles (09/2015 - 02/2002)|
|2.||Rothenberg, Marc E: 32 articles (01/2015 - 06/2002)|
|3.||Elias, Jack A: 32 articles (06/2012 - 03/2002)|
|4.||McKenzie, Andrew N J: 30 articles (08/2014 - 02/2002)|
|5.||Brombacher, Frank: 28 articles (11/2014 - 10/2002)|
|6.||Wynn, Thomas A: 26 articles (08/2015 - 01/2003)|
|7.||Gelfand, Erwin W: 25 articles (02/2015 - 12/2002)|
|8.||Takeda, Katsuyuki: 24 articles (02/2015 - 12/2002)|
|9.||Homer, Robert J: 23 articles (12/2014 - 01/2002)|
|10.||Finkelman, Fred D: 23 articles (05/2012 - 10/2002)|
|1.||Asthma (Bronchial Asthma)
07/01/2002 - "To investigate the role of IL-13 in chronic asthma, using an improved experimental model of asthma that reproduces most of the morphological features of the human disease. "
09/01/2006 - "These data support the view that targeting IL-13 may be beneficial in the treatment of asthma."
04/01/2006 - "GM1E7 is superior to available agents interfering with IL-13 activity in terms of specificity and efficiency and offers potential novel therapeutic perspectives for the treatment of allergic asthma."
05/15/2008 - "Drugs that block the biological function of IL-13 may be an effective treatment for asthma. "
01/01/2002 - "However, well designed asthma clinical trials are warranted to determine with certainty, the efficacy of therapies based on IL-4/IL-13 blockade."
11/27/2012 - "Compared to the asthmatic group, the BALF and serum levels of IL-13 were significantly lower [(34.7 ± 7.1) vs (105.0 ± 9.0) ng/L, (34.0 ± 4.7) vs (48.1 ± 6.1) ng/L] (both P = 0.000) and the number of CD4⁺CD25⁺Foxp3⁺ regulatory T cells increased in peripheral blood (8.0% ± 1.3% vs 5.1% ± 2.1%, P = 0.002) and airway inflammation was significantly relieved in the cell treatment group. "
05/01/2015 - "Ten original research articles were found, reporting promising results for some candidate genes in drug metabolism (TYMS, MTHFR), DNA repair (XRCC1, OGG1, CCND1) and inflammation (SOD2, TGFB1)/immunity (IL13) pathways, but with no firm conclusion. "
01/01/2007 - "Inhibition of IL-4/IL-13 does not enhance the efficacy of allergen immunotherapy in murine allergic airway inflammation."
09/01/2010 - "This study demonstrates that both PARP-1 protein and activity are increased by allergen-activated inflammatory mediators, excluding IL13, and that PARP-1 increase does not appear necessary for GCM, one of the characteristic markers of allergic airway inflammation in murine models."
02/01/2010 - "In this study, we asked the question of whether IL-13 is a major contributor to the observed difference in features of inflammation between HL and PMBCL. "
11/01/2014 - "This was due to IL-13 signaling that was advantageous for resolving MRSA infection via inhibition of IFN-γ, but was detrimental to the clearance of influenza virus. "
02/01/2014 - "IL-13 driven Th2 immunity is indispensable for host protection against infection with the gastrointestinal nematode Nippostronglus brasiliensis. "
02/01/2015 - "In this study, we hypothesized that RV infection of allergen-treated mice results in IL-13 production by CD11b+ exudative macrophages in vivo. "
01/01/2014 - "This study investigated the involvement of IL-13 and tTG in liver fibrogenesis during Sj infection in mice. "
04/01/2010 - "Further positional and/or functional candidate genes investigated TLR2, IL13, IL17A, IL28R, TACE/ADAM 17 and GBP1, were not associated with infection in this study. "
08/01/2002 - "IV administration of 150 or 200 micro g/kg/day of IL-13 cytotoxin for 7 days was lethal to nude mice, whereas 200 micro g/kg/day X 7 days of CI administration was highly effective in the regression of established tumors without any toxicities. "
08/01/1995 - "Thus, anti-tumor effects of IL-13 in vivo most probably result from pleiotropic effects including recruitment of nonspecific cells and improved stimulation of immune-specific anti-tumor effectors."
01/01/2003 - "administration of IL-13 cytotoxin mediated marked regression of established tumors with complete remission. "
11/01/2012 - "Our aim was partially realized with improved recognition of tumor and reduced but persisting activity against normal tissue IL13Rα1(+) cells by the IL13.E13K.R109K CAR. "
09/15/2004 - "In this study, we have generated an IL-13 cytotoxin IL13E13K-PE38, in which IL-13 antagonist is fused to PE to determine whether this molecule has improved cytotoxicity to tumor cells compared with wild type (wt)IL13-PE38. "
03/01/2008 - "Finally, while IL-13 blockade was highly efficacious in wild-type mice, the development of fibrosis in CAT2(-/-) mice was largely IL-13-independent. "
08/01/2001 - "Here, IL-13 antagonism was highly efficacious, even after fibrosis and the Th2 cytokine response were firmly established. "
06/15/2011 - "Neutralization of TSLP or genetic deletion of TSLPR in IL-13 transgenic mice resulted in a significant reduction in fibrocytes and in skin fibrosis. "
01/01/2015 - "Notably, we show that pharmacologic inhibition of IL-4/IL-13 in human ex vivo studies as well as in established mouse CP decreases pancreatic AAMs and fibrosis. "
01/01/2015 - "Recent studies reported that alternatively activated (M2) macrophages enhanced Th2 immune responses and fibrosis by production of pro-fibrotic factors (IL-10, IL-13 and CCL18). "
|1.||Interleukin-4 (Interleukin 4)
|2.||Interleukin-5 (Interleukin 5)
|4.||Immunoglobulin E (IgE)
|6.||Interleukin-10 (Interleukin 10)
|7.||Messenger RNA (mRNA)
|9.||Interleukin-12 (IL 12)
|3.||Drug Therapy (Chemotherapy)